Literature DB >> 20719242

Drug targeting to the kidney: Advances in the active targeting of therapeutics to proximal tubular cells.

M E M Dolman1, S Harmsen, G Storm, W E Hennink, R J Kok.   

Abstract

Activated signaling cascades in the proximal tubular cells of the kidneys play a crucial role in the development of tubulointerstitial fibrosis. Inhibition of these signaling cascades with locally delivered therapeutics is an attractive approach to minimize the risk of unwanted side effects and to enhance their efficacy within the renal tissue. This review describes the potential avenues to actively target drugs to proximal tubular cells by recognition of internalizing receptors and how drug carriers can reach this cell type from either the apical or basolateral side. Important characteristics of drug carrier systems such as size and charge are discussed, as well as linking technologies that have been used for the coupling of drugs to the presented carrier systems. Lastly, we discuss the cellular handling of drugs by proximal tubular cells after their delivery to the kidneys.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20719242     DOI: 10.1016/j.addr.2010.07.011

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  21 in total

1.  Renal-targeting triptolide-glucosamine conjugate exhibits lower toxicity and superior efficacy in attenuation of ischemia/reperfusion renal injury in rats.

Authors:  Yu Fu; Qing Lin; Tao Gong; Xun Sun; Zhi-Rong Zhang
Journal:  Acta Pharmacol Sin       Date:  2016-07-11       Impact factor: 6.150

2.  Mesoscale nanoparticles selectively target the renal proximal tubule epithelium.

Authors:  Ryan M Williams; Janki Shah; Brandon D Ng; Denise R Minton; Lorraine J Gudas; Christopher Y Park; Daniel A Heller
Journal:  Nano Lett       Date:  2015-03-26       Impact factor: 11.189

Review 3.  Receptors, endocytosis, and trafficking: the biological basis of targeted delivery of antisense and siRNA oligonucleotides.

Authors:  R L Juliano; K Carver; C Cao; X Ming
Journal:  J Drug Target       Date:  2012-11-19       Impact factor: 5.121

Review 4.  Diverse origins of the myofibroblast—implications for kidney fibrosis.

Authors:  Lucas L Falke; Shima Gholizadeh; Roel Goldschmeding; Robbert J Kok; Tri Q Nguyen
Journal:  Nat Rev Nephrol       Date:  2015-01-13       Impact factor: 28.314

5.  Targeting Anti-TGF-β Therapy to Fibrotic Kidneys with a Dual Specificity Antibody Approach.

Authors:  Steve McGaraughty; Rachel A Davis-Taber; Chang Z Zhu; Todd B Cole; Arthur L Nikkel; Meha Chhaya; Kelly J Doyle; Lauren M Olson; Gregory M Preston; Christine M Grinnell; Katherine M Salte; Anthony M Giamis; Yanping Luo; Victor Sun; Andrew D Goodearl; Murali Gopalakrishnan; Susan E Lacy
Journal:  J Am Soc Nephrol       Date:  2017-08-21       Impact factor: 10.121

Review 6.  Nanomedicines for renal disease: current status and future applications.

Authors:  Nazila Kamaly; John C He; Dennis A Ausiello; Omid C Farokhzad
Journal:  Nat Rev Nephrol       Date:  2016-10-31       Impact factor: 28.314

Review 7.  Recent Advances in the Synthesis of Complex Macromolecular Architectures Based on Poly(N-vinyl pyrrolidone) and the RAFT Polymerization Technique.

Authors:  Nikoletta Roka; Olga Kokkorogianni; Philippos Kontoes-Georgoudakis; Ioannis Choinopoulos; Marinos Pitsikalis
Journal:  Polymers (Basel)       Date:  2022-02-11       Impact factor: 4.329

8.  Epac-Rap signaling reduces oxidative stress in the tubular epithelium.

Authors:  Geurt Stokman; Yu Qin; Tijmen H Booij; Sreenivasa Ramaiahgari; Marie Lacombe; M Emmy M Dolman; Kim M A van Dorenmalen; Gwendoline J D Teske; Sandrine Florquin; Frank Schwede; Bob van de Water; Robbert J Kok; Leo S Price
Journal:  J Am Soc Nephrol       Date:  2014-02-07       Impact factor: 10.121

Review 9.  Nanomedicines for kidney diseases.

Authors:  Ryan M Williams; Edgar A Jaimes; Daniel A Heller
Journal:  Kidney Int       Date:  2016-06-09       Impact factor: 10.612

10.  Kidney-Targeted Epoxyeicosatrienoic Acid Analog, EET-F01, Reduces Inflammation, Oxidative Stress, and Cisplatin-Induced Nephrotoxicity.

Authors:  John D Imig; Md Abdul Hye Khan; Anna Burkhan; Guan Chen; Adeniyi Michael Adebesin; John R Falck
Journal:  Int J Mol Sci       Date:  2021-03-10       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.